A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of the Safety, Tolerability and Efficacy Following Sequential Dose Regimens of Lu 31-130 to Patients With Schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Zicronapine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 09 Dec 2009 Actual patient number (280) added as reported by ClinicalTrials.gov.
- 08 Dec 2009 Status changed from active, no longer recruiting to completed.
- 01 May 2009 Planned number of patients changed from 210 to 300 as reported by ClinicalTrials.gov.